Search Results
Jun 07, 2026, 23:00 ET GIGABYTE Advances Motherboard Performance with AI-driven Technologies
platform. At the core of GIGABYTE's AI-enhanced innovation is X3D Turbo Mode 2.0, designed to maximize AMD Ryzen™ X3D processor performance through a dynamic AI overclocking engine and a dedicated onboard hardware chip. The exclusive OC engine is trained on massive datasets and optimized for per-processor
More news about: GIGABYTE
Jun 07, 2026, 23:00 ET GIGABYTE Advances Motherboard Performance with AI-driven Technologies
platform. At the core of GIGABYTE's AI-enhanced innovation is X3D Turbo Mode 2.0, designed to maximize AMD Ryzen™ X3D processor performance through a dynamic AI overclocking engine and a dedicated onboard hardware chip. The exclusive OC engine is trained on massive datasets and optimized for per-processor
More news about: GIGABYTE
Jun 07, 2026, 22:45 ET HTX Launches "Appreciation Program" with Over $10 Million to Reward User Trust
shifts in market conditions, the relationship between trading platforms and their users is being fundamentally redefined. As the era of aggressive user acquisition fades, "long-term companionship and mutual trust" is emerging as the most valuable asset for weathering bull and bear cycles alike.
More news about: HTX
Jun 07, 2026, 22:19 ET Unisound Releases U2: A Native Agentic Large Model Built for Execution, Capable of Autonomously Decomposing and Completing 100+ Steps in Complex Real-World Workflows
to explicit Chain-of-Thought, using deterministic Tokens for precise derivation and result convergence.This means U2 is not simply shortening the reasoning chain. It is reconstructing the division of labor in model thinking: high-cost stages such as open-ended exploration and path planning are
More news about: Unisound
Jun 07, 2026, 22:03 ET Unisound Releases U2: A Native Agentic Large Model Built for Execution, Capable of Autonomously Decomposing and Completing 100+ Steps in Complex Real-World Workflows
to explicit Chain-of-Thought, using deterministic Tokens for precise derivation and result convergence.This means U2 is not simply shortening the reasoning chain. It is reconstructing the division of labor in model thinking: high-cost stages such as open-ended exploration and path planning are
More news about: Unisound
Jun 07, 2026, 21:40 ET Vi Appoints Spencer Honeyman as President, Global Growth
automation.As Vi continues to scale globally, the company remains focused on its larger vision: health abundance in our lifetime - a future where healthcare is more precise, predictive, accessible and affordable for all.Media Contact:Email:
More news about: Vi Labs
Jun 07, 2026, 21:28 ET Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
development," said Baohui Yu, CEO of Dayspring Pharma.Dayspring Pharma is currently engaging with regulatory authorities to define the next phase of clinical development.About CG2001CG2001 is a topical combination of minoxidil and finasteride developed to harness the synergistic
More news about: Dayspring Pharma
Jun 07, 2026, 21:00 ET Uhale Adopts Quokka's Q-mast to Strengthen Application Security Testing
vulnerabilities, privacy risks, and compliance gaps earlier in the development process."Security is a continuous process," said Lewis Zhang, R&D General Manager at Uhale. "Adding Q-mast to our workflow is a practical step to strengthen our testing capabilities. It gives us additional visibility as we
More news about: Uhale
Jun 07, 2026, 21:00 ET New Report "Early Bird" Maps Tech Investing for Asian Family Offices
Consulting Andrew is the Founder of Deane Consulting and an established expert in the wealth management industry. Andrew specializes in strategic development and thought leadership, focusing on the global wealth trends, family offices and AI technology. He is an advisor to board level including
More news about: Annum Capital
Jun 07, 2026, 21:00 ET New Report "Early Bird" Maps Tech Investing for Asian Family Offices
Consulting Andrew is the Founder of Deane Consulting and an established expert in the wealth management industry. Andrew specializes in strategic development and thought leadership, focusing on the global wealth trends, family offices and AI technology. He is an advisor to board level including
More news about: Annum Capital
Jun 07, 2026, 21:00 ET Anamana Incubator Targets Culturally Native Creators to Diversify Homogenized Micro-Drama Market
SINGAPORE, June 7, 2026 /PRNewswire/ -- Anamana, the platform for AI-native micro-serials, is using its Anamana 100 Creator Incubator to attract culturally native creators with the ambition to tell culture-driven narratives in the vertical
More news about: Anamana
Jun 07, 2026, 21:00 ET GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
PRO, powered by AI Sensor Technology that automatically monitors user presence, ambient lighting, and pixel cleaning. Complementing AI OLED CARE PRO is an enhanced thermal design featuring integrated heat pipes and advanced thermal materials. The FO27Q28G delivers a 12% reduction in T-Con temperature,
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
PRO, powered by AI Sensor Technology that automatically monitors user presence, ambient lighting, and pixel cleaning. Complementing AI OLED CARE PRO is an enhanced thermal design featuring integrated heat pipes and advanced thermal materials. The FO27Q28G delivers a 12% reduction in T-Con temperature,
More news about: GIGABYTE
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
Triple Agonist Peptide: ASC37ASC37 is an oral GLP-1R/GIPR/GCGR triple agonist peptide developed using Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT). By impeding enzymatic degradation and increasing GI permeability, POTENT is able to increase the oral bioavailability
More news about: Ascletis Pharma Inc.
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
as of the date of this release. The Company wishes to clarify that this announcement is intended solely to communicate research and clinical development progress, is for reference by healthcare professionals only, is not promotional in nature, and does not constitute a recommendation for the use of any
More news about: Oricell Therapeutics Holdings Limited
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
induction and immune tolerance.Mechanism of Action: ATG-207 is designed to localize activity to T cells through CD3 engagement while delivering controlled, TGFβRIII-biased TGF-β signaling. Its dynamic masking is intended to reduce systemic receptor engagement and limit off-target TGF-β
More news about: Antengene Corporation Limited
Jun 07, 2026, 20:00 ET UPST Deadline: UPST Investors Have Opportunity to Lead Upstart Holdings, Inc. Securities Fraud Lawsuit
Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving
More news about: THE ROSEN LAW FIRM, P. A.
Jun 07, 2026, 18:52 ET Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
NOW:File to be lead plaintiff by July 17, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action.THE LEAD PLAINTIFF PROCESS FOR SPORTRADAR GROUP
More news about: Kessler Topaz Meltzer & Check, LLP
Jun 07, 2026, 18:30 ET VolitionRx Announces Pricing of $4.6 Million Public Offering
under the securities laws of any such state or other jurisdiction.About VolitionVolition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through
More news about: VolitionRx Limited
Jun 07, 2026, 18:13 ET FSK Investors Have Opportunity to Lead FS KKR Capital Corp. Securities Fraud Lawsuit
Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving
More news about: THE ROSEN LAW FIRM, P. A.
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
CagriSemaOnce-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analog,
More news about: NOVO NORDISK INC.
Jun 07, 2026, 17:30 ET Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
Amylin, a hormone produced in the pancreas along with insulin, is emerging as therapeutic target for diabetes and obesity. Amylin helps balance blood glucose levels and makes people feel full after eating. Amylin agonists—synthetic
More news about: American Diabetes Association
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
dysfunction.2 Leveraging 40+ years of cutting-edge science and human genetics, Amgen is redefining cardiometabolic care and risk management. With years of success in cardiovascular disease with Repatha, Amgen is well positioned to deliver potential breakthrough medicines like MariTide and olpasiran
More news about: Amgen
Jun 07, 2026, 16:45 ET Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
fully managed by current treatments."CORE-OLE (NCT05681351), an open-label extension study of CORE-TIMI 72a and CORE2-TIMI 72b, is ongoing. The results from CORE-OLE is expected to provide insights on the long-term efficacy and safety of olezarsen in this high-risk population.Simultaneously
More news about: American Diabetes Association
Jun 07, 2026, 14:30 ET Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
MASH."There is a critical need for treatments that also drive meaningful improvements in overall metabolic health, and these findings are encouraging for potential new solutions," said Carel le Roux, MD, PhD, lead author of the study. "For patients, improving metabolic health is about more than weight
More news about: American Diabetes Association